ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

IDXG // Interpace Biosciences Inc.

FA <GO> NASDAQ RQD COCKPIT → CIK 0001054102 ↗
Industrials • Diversified Equities
$5.72 ▲ +0.77 (+15.56%)
MKT CAP: $23.2M • VOL: 5.1K
IDXG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
LINE ITEM (USD / %)
FY 2025
FILED 2025-12-31
FY 2024
FILED 2024-12-31
FY 2023
FILED 2023-12-31
Revenue (Total Sales) $38.7M $46.9M $40.0M
YoY Revenue Growth % -17.5% +17.2% —
Gross Profit $24.1M $29.9M —
Gross Margin % 62.3% 63.8% —
Research & Development (R&D) — — —
Operating Income (EBIT) $4.1M $8.1M $4.0M
Operating Margin % 10.5% 17.3% 9.9%
Net Income (GAAP) $24.6M $6.7M $2.0M
EBITDA (Normalized) $4.4M $8.8M —
Diluted EPS ($/sh) — — —
Operating Cash Flow (OCF) $5.8M $4.6M $3.8M
Capital Expenditures (CapEx) $356.0K $876.0K —
Free Cash Flow (FCF) $5.5M $3.8M $3.8M
FCF Margin % 14.1% 8.0% 9.5%
Return on Invested Capital (ROIC %) 16.2% 95.0% —
Cash & Short-Term Equivalents $2.5M $1.5M —
Total Debt (Short + Long Term) — — —
Total Stockholders' Equity $22.4M -$2.2M —